Botanical research centers
This article was originally published in The Tan Sheet
NCCAM and NIH's Office of Dietary Supplements are co-funding five-year grants for five research centers investigating "a variety of widely consumed botanicals from flaxseed to tarragon," NCCAM Director Stephen Straus, MD, announces April 7. The Memorial Sloan-Kettering Cancer Center in New York will research botanicals that may modulate immune function, including echinacea and Chinese herbal formulations. Metabolic syndrome, obesity and diabetes are the focus of a partnership between Rutgers and Louisiana State University. Other study areas include anti-inflammatory actions of botanical lipids at Wake Forest and Harvard; women's health at the University of Illinois-Chicago; and age-related diseases at Purdue, Rutgers and the University of Alabama. First-year funding for all five combined totals about $6.75 mil...
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.